Lepodisiran is a small interfering RNA that was developed to reduce lipoprotein in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company. From Wikipedia
The siRNA-based drug shows promise as the first treatment for high lipoprotein(a) levels, with Phase 3 trials underway to assess its impact on cardiovascular events.
